Attention Deficit Hyperactivity Disorder Market Report 2026

Attention Deficit Hyperactivity Disorder Market Overview

• Attention Deficit Hyperactivity Disorder market size has reached to $17.38 billion in 2025 • Expected to grow to $23.8 billion in 2030 at a compound annual growth rate (CAGR) of 6.4% • Growth Driver: The Growing Adoption Of Personalized Medicine Is Driving The Market • Market Trend: Integration Of Digital Therapeutics In ADHD Treatment With Launch Of EndeavorOTC • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Attention Deficit Hyperactivity Disorder Market?

Attention deficit hyperactivity disorder (ADHD) is a neurodevelopmental condition characterized by persistent inattention, hyperactivity, and impulsivity that interfere with daily functioning. It begins in childhood and can continue into adulthood, affecting focus, self-control, and organization. Treatment may include behavioral therapy, medication, and lifestyle adjustments. The main types of attention deficit hyperactivity disorder (ADHD) treatment include stimulants and non-stimulants. Stimulants are medications that enhance brain activity to improve focus, attention, and impulse control, commonly used for ADHD treatment. ADHD treatment is categorized by age group into children and adults, and by gender into male and female. ADHD drugs are available in various dosage forms, including tablets, capsules, and other forms, and are distributed through multiple channels, such as retail pharmacies, hospital pharmacies, and online pharmacies.

What Is The Attention Deficit Hyperactivity Disorder Market Growth Forecast?

The attention deficit hyperactivity disorder market size is expected to see strong growth in the next few years. It will grow to $23.8 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to increasing demand for long-acting medication formulations, rising focus on holistic mental health management, expansion of telepsychiatry services, growing investments in digital mental health platforms, increasing research into non-stimulant therapeutic options. Major trends in the forecast period include increasing adoption of non-stimulant medications, rising use of digital therapeutics and monitoring tools, growing focus on adult adhd diagnosis, expansion of personalized treatment approaches, enhanced integration of behavioral and pharmacological therapies.

Global Attention Deficit Hyperactivity Disorder Market Segmentation

1) By Type: Stimulants, Non-Stimulants 2) By Age Group: Children, Adults 3) By Gender: Male, Female 4) By Dosage Form: Tablets, Capsules, Other Dosage Forms 5) By Distribution Channel: Retail Pharmacy, Hospital Pharmacy, Online Pharmacy Subsegments: 1) By Stimulants: Methylphenidate-based Medications, Amphetamine-based Medications, Mixed Amphetamine Salts, Dexmethylphenidate 2) By Non-Stimulants: Atomoxetine (Strattera), Guanfacine (Intuniv), Clonidine (Kapvay)

What Is The Driver Of The Attention Deficit Hyperactivity Disorder Market?

The growing adoption of personalized medicine is expected to propel the growth of the attention deficit hyperactivity disorder (ADHD) market going forward. Personalized medicine is a medical approach that tailors treatments to an individual's genetic, environmental, and lifestyle factors for more precise and effective healthcare. The adoption of personalized medicine is attributed to advancements in genomic technologies, which enable the tailoring of treatments based on an individual's genetic profile, leading to more effective and targeted therapies. Attention deficit hyperactivity disorder (ADHD) contributes significantly to personalized medicine by facilitating customized treatment strategies that consider an individual’s unique genetic, environmental, and behavioral characteristics, resulting in more effective and targeted interventions. For instance, in February 2024, according to a report published by the Personalized Medicine Coalition (PMC), a US-based non-profit organization, in 2023, personalized medicines accounted for over a third of new FDA drug approvals for the fourth consecutive year. The FDA approved 16 new personalized treatments for rare diseases (up from 6 in 2022), 7 cancer drugs, and 3 for other conditions. Therefore, the growing adoption of personalized medicine is driving the growth of the attention deficit hyperactivity disorder industry.

Key Players In The Global Attention Deficit Hyperactivity Disorder Market

Major companies operating in the attention deficit hyperactivity disorder market are Takeda Pharmaceutical Company Limited, Pfizer Inc., Novartis International AG, Eli Lilly and Company, Johnson & Johnson, AstraZeneca PLC, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Supernus Pharmaceuticals Inc., Tris Pharma Inc., Mallinckrodt Pharmaceuticals plc, Arbor Pharmaceuticals LLC, KemPharm Inc., Cingulate Therapeutics LLC, Adlon Therapeutics L.P., Ironshore Pharmaceuticals Inc., Rhodes Pharmaceuticals L.P., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals Inc., Alkem Laboratories Ltd.

Global Attention Deficit Hyperactivity Disorder Market Trends and Insights

Major companies are operating in the ADHD market, focusing on developing technological advancements such as video game–based digital therapeutics to provide non-pharmacological interventions, improve attention management, and enhance patient engagement. A video game–based digital therapeutic delivers interactive, adaptive cognitive training via mobile devices using real-time performance tracking and closed-loop algorithms to improve focus, attention control, and executive functioning compared to traditional stimulant or non-stimulant medications. For instance, in June 2024, Akili Interactive, a US-based digital health company, launched EndeavorOTC, the first FDA-cleared over-the-counter digital therapeutic for adult ADHD. The product uses Akili’s patented “Selective Stimulus Management Engine” to present multitasking and attention-challenging game tasks, automatically adjusting difficulty based on user performance. In a six-week pivotal study, 83% of participants showed improved attentional control, and users reported enhanced productivity and quality of life.

What Are Latest Mergers And Acquisitions In The Attention Deficit Hyperactivity Disorder Market?

In September 2024, Collegium Pharmaceutical Inc., a US-based specialty pharmaceutical company, acquired Ironshore Therapeutics Inc. for $525 million. This acquisition aims to expand its product portfolio beyond pain management and establish a presence in the growing ADHD market with the differentiated product Jornay PM. Ironshore Therapeutics Inc. is a US-based company focused on developing and commercializing therapies for attention deficit hyperactivity disorder (ADHD).

Regional Outlook

North America was the largest region in the attention deficit hyperactivity disorder market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Attention Deficit Hyperactivity Disorder Market?

The attention deficit hyperactivity disorder market consists of revenues earned by entities by providing services such as diagnosis, therapy, counselling, medication management, and digital health solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The attention deficit hyperactivity disorder (ADHD) market also includes sales of medical devices, digital therapeutics, and assistive learning tools. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Attention Deficit Hyperactivity Disorder Market Report 2026?

The attention deficit hyperactivity disorder market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the attention deficit hyperactivity disorder industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.